Hostname: page-component-cd9895bd7-q99xh Total loading time: 0 Render date: 2024-12-24T02:35:49.488Z Has data issue: false hasContentIssue false

P.081 Evolving treatment of pediatric-onset multiple sclerosis in Alberta

Published online by Cambridge University Press:  24 June 2022

C Yearwood
Affiliation:
(Edmonton)
C Wilbur
Affiliation:
(Edmonton)*
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.

Background: Pediatric-onset multiple sclerosis (MS) is associated with a high rate of disease activity. However, only a single DMT – fingolimod – has been approved by Health Canada for children, in 2018. In this study, we describe trends in the treatment of pediatric-onset MS in Alberta. Methods: We performed a retrospective review of Alberta administrative health databases, identifying cases of MS under 19 years of age from January 1, 2011 - December 31, 2020. Pharmacy dispenses of MS DMTs were identified by Anatomical Therapeutic Chemical classification code and grouped as injectables (glatiramer acetate, interferon-beta) or newer agents (all others). Results: 79 incident cases of pediatric MS were identified during the study period. 47/79 (59%) had at least one DMT dispense, with the first dispense occurring a median 263 days (IQR 134.5-988) from the index date at a median age of 17.2 years (IQR 16.0-18.6). Injectables accounted for all initial DMT dispenses < 19 years of age prior to 2019, while from 2019-2020 injectables accounted for only 3/15 (20%) initial dispenses, with rituximab (5/15, 33%) being the most common initial DMT in those years. Conclusions: The treatment of children with MS in Alberta has rapidly evolved, shifting shift towards earlier treatment using newer high-efficacy agents.

Type
Poster Presentations
Copyright
© The Author(s), 2022. Published by Cambridge University Press on behalf of Canadian Neurological Sciences Federation